Efficacy Screening Of Antibody-Drug-Conjugates By Surface Plasmon Resonance

By Helen Hsu, Jeff Carroll, Jason Ramsay, Lisa McDermott, Agata Burzawa, and Elinor George

The unique target-specific binding of ADCs allows targeted delivery of cytotoxic small molecules to cancer cells and thus expands the therapeutic window. Prior to deploying ADCs to in vivo systems, the characteristic of in vitro efficacy must be evaluated for candidate selection.

In vitro efficacy evaluation of an ADC provides valuable insights for preliminary candidate selection at the preproduction development phase to maximize therapeutic outcomes in the clinic. Assays including cytotoxicity, antigen binding affinity, internalization, and Fc-mediated toxicity are extensively assessed.

Rapid screening of ADC affinity using surface plasmon resonance (SPR) provides preliminary efficacy data in comparison of antigen binding affinity of ADC with selected linkers and payloads to the non-conjugated antibody.